Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 1, 2025
Reporting Period: Full Year 2025 (FY 2025) guidance reaffirmation.
Context: The filing discloses that senior management is scheduled to meet with investors and analysts between December 1, 2025, and December 31, 2025, to reaffirm previously issued financial guidance.
Key Financial Metrics and Guidance
The filing provides specific earnings per share (EPS) guidance for the year ending December 31, 2025. No revenue, profit, cash flow, margin, debt, or liquidity figures are provided in this specific document.
| Metric | Value (FY 2025 Guidance) |
|---|---|
| GAAP Diluted EPS | Approximately $12.26 |
| Adjusted (Non-GAAP) EPS | Approximately $17.00 |
Note: Adjusted EPS is a non-GAAP measure used by management to analyze core operating performance. It excludes specific items such as amortization of intangibles, valuation adjustments, and litigation settlements.
Material Changes and Reconciliation Items
The filing details the reconciliation between GAAP EPS and Adjusted EPS, highlighting specific items impacting the difference between the two metrics:
- Add-backs to GAAP EPS:
- Amortization of identifiable intangibles: $0.42
- Put/call valuation adjustments: $3.81
- Value creation initiatives: $2.65
- Settlement of certain litigation expenses: $0.13
- Loss on sale of business: $0.52
- Impairment charges: $0.27
- Deductions from GAAP EPS:
- Impact of exit of employer group commercial products business: ($0.52)
- Cumulative net tax impact: ($2.54)
The filing states that the Company does not expect changes to its FY 2025 Adjusted EPS guidance but anticipates potential changes to its FY 2025 GAAP EPS guidance due to ongoing value creation and strategic initiatives.
Outlook, Risks, and Management Commentary
Management Commentary: Management intends to reaffirm the guidance issued on November 5, 2025, during upcoming investor meetings. They emphasize that Adjusted EPS provides a comprehensive perspective on core operating performance and is used for planning and incentive compensation.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. These statements are subject to risks, uncertainties, and assumptions, including those detailed in the "Risk Factors" section of the Company's other SEC filings. The guidance excludes the impact of future value changes to items not yet recognized or reasonably estimated.
Investor Verification Checklist
- Verify the November 5, 2025 press release to confirm the original issuance of the $12.26 GAAP and $17.00 Adjusted EPS guidance.
- Review the "Risk Factors" section in the Company's most recent 10-K or 10-Q to understand specific risks affecting the forward-looking statements.
- Monitor upcoming investor meetings between December 1 and December 31, 2025, for any updates on the potential changes to GAAP EPS guidance.
- Confirm the specific details of the "exit of employer group commercial products business" and "value creation initiatives" in other filings to understand the magnitude of these non-GAAP adjustments.